%0 Journal Article
%T Efficacy of tacrolimus monotherapy in primary membranous nephropathy.
%A Zhang YP
%A Ran L
%A Guo L
%A Gou YL
%A Guo SS
%A Xu Y
%A Hua X
%A Chen H
%J Open Med (Wars)
%V 19
%N 1
%D 2024
%M 38841175
暂无%R 10.1515/med-2024-0957
%X <B>UNASSIGNED: </B>The aim of this study was to observe the remission of primary membranous nephropathy (PMN) and evaluate the efficacy of tacrolimus (TAC) monotherapy for PMN in comparison with TAC combined with a low-dose glucocorticoid (GC) protocol (TAC + GC).<BR><B>UNASSIGNED: </B>This was tested in a prospective monocentric observational trial of 70 patients with PMN, of whom 34 received TAC (0.05-0.075 mg/kg/day) or 36 received TAC (0.05-0.075 mg/kg/day) and GC (0.3-0.5 mg/kg/day of prednisone).<BR><B>UNASSIGNED: </B>At 3, 6, 9, and 12 months of treatment, the effective rates in the TAC group and the TAC + GC group were similar (P > 0.05). The urinary protein quantification was reduced in patients under both therapeutic protocols, and the differences in the proteinuria quantification at 3, 6, 9, and 12 months of treatment were not statistically significant between the two groups (P > 0.05). The overall incidence of adverse reactions in the TAC group was lower than that in the TAC + GC group (23.5% < 36.1%), and the difference was statistically significant (P < 0.05).<BR><B>UNASSIGNED: </B>TAC monotherapy for PMN could effectively reduce urinary protein quantification and increase serum albumin levels. Compared with TAC + GC, TAC monotherapy for PMN had no difference in efficacy and fewer incidences of adverse reactions.